Cell Core C continues FSHD biomaterials acquisition to support Projects 1, 2, and 3, as well as the FSHD research community with our cell repository distribution program. A new focus on FSHD families with nonmanifesting carriers of the genetic signature will expand on the usefulness of our repository by providing DNA from blood, muscle biopsy tissue and cells derived from biopsies for investigating modifiers of FSHD pathology. Subjects recruited into the program with confirmatory genetic testing will be asked to participate and give informed consent. Biceps muscles, which tend to be affected early in FSHD pathology, will be biopsied and coded to mask patient identity (Aim 1). Biopsy material will be distributed for histology (Aim 2), RNA screening (Proj. 2, Aim 1), which will inform xenograft studies (Proj. 3, Aims 1&2), and fiber-based xenografts (Proj. 3, Aim 1). Primary muscle cells will be isolated (Aim 2) and expanded for banking and distribution (Aim 3);CD56+ muscle cells will be provided to Center investigators for RNA screening (Proj. 2, Aim 1), study of the epigenetic regulation of DUX4-fl (Proj. 2, Aim 2), the development of antisense morpholino drugs (Proj. 2, Aim 3) and for cell-based xenografts (Proj. 3, Aim 2). Cell availability is advertised on the FSH Society and Center websites and at the annual FSHD Research International Consortium Meeting. Finally, the Bioinformatics Core (Aim 4) will be responsible for managing databases of integrated clinical and experimental data, and provide bioinformatic support to whole genome/exome studies (Proj. 1, Aim 2), whole transcriptome sequencing studies (Proj. 2, Aim 1 &3), biomarker validation (Proj. 2, Aim 1), validation of cell-based xenografts (Proj. 3, Aim 2), evaluation of AAV and morpholino antisense drugs (Proj.
2 Aim 3 and Proj.
3 Aims 1 &2) and developmental screening for DUX4 target genes (Proj. 3, Aim 4).

Public Health Relevance

The functions of Cell Core C are vital to the Center, providing both biomaterials and bioinformatic support to all projects. In addition to supporting Center investigators. Cell Core C distributes characterized primary FSHD and control muscle cells to labs performing FSHD or other muscular dystrophy research.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
United States
Zip Code
Zhang, Yuanfan; King, Oliver D; Rahimov, Fedik et al. (2014) Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum Mol Genet 23:3180-8
Mitsuhashi, Hiroaki; Mitsuhashi, Satomi; Lynn-Jones, Taylor et al. (2013) Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum Mol Genet 22:568-77
Rahimov, Fedik; Kunkel, Louis M (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201:499-510
Homma, Sachiko; Chen, Jennifer C J; Rahimov, Fedik et al. (2012) A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet 20:404-10
Homma, Sachiko; Beermann, Mary Lou; Miller, Jeffrey Boone (2011) Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-?2-deficient mouse model of congenital muscular dystrophy. Hum Mol Genet 20:2662-72
Reed, Patrick W; Bloch, Robert J (2011) Crystallin-gazing: unveiling enzymatic activity. J Neurochem 118:315-6
Roche, Joseph A; Ford-Speelman, Diana L; Ru, Lisa W et al. (2011) Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation. Am J Physiol Cell Physiol 301:C1239-50
Rahimov, Fedik; King, Oliver D; Warsing, Leigh C et al. (2011) Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor. Physiol Genomics 43:398-407
Arashiro, Patricia; Eisenberg, Iris; Kho, Alvin T et al. (2009) Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci U S A 106:6220-5
Vishnudas, Vivek K; Miller, Jeffrey Boone (2009) Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. Hum Mol Genet 18:4467-77